Elite Journal of Medical Sciences. Volume 2 issue 7(2024), 58-65
https://epjournals.com/journals/EJMS

Role of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell disease (SCD) is a hereditary hematological disorder characterized by the presence of hemoglobin S (HbS), leading to the sickling of red blood cells (RBCs) and resultant vaso-occlusive crises (VOC). The reticuloendothelial system (RES), comprising macrophages and the endothelial lining of blood vessels, plays a pivotal role in the pathophysiology of SCD, particularly regarding vaso-occlusion. This review examines the multifaceted contributions of the RES to the mechanisms underlying vaso-occlusive events in SCD, including the clearance of sickled RBCs, inflammatory responses, and interactions with the immune system. Macrophages in the RES are responsible for the recognition and phagocytosis of sickled RBCs, a process that can lead to the release of pro-inflammatory cytokines. This inflammatory response can exacerbate endothelial dysfunction, promoting the adhesion of sickled cells and leukocytes to the vascular endothelium and ultimately leading to microvascular obstruction. Additionally, the function of the spleen as a component of the RES is compromised in individuals with SCD, further complicating the clearance of abnormal RBCs and increasing the risk of vaso-occlusive crises.

Keywords*: sickle cell disease, vaso-occlusive crisis, reticuloendothelial system, macrophages, inflammation, immune response, therapeutic targets.*

Introduction

Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal hemoglobin S (HbS), resulting from a single nucleotide mutation in the β-globin gene. This abnormal hemoglobin causes red blood cells (RBCs) to adopt a rigid, sickle shape under conditions of low oxygen tension. The sickling of RBCs leads to a range of clinical complications, primarily vaso-occlusive crises (VOCs), which are episodes of acute pain and tissue ischemia due to the obstruction of small blood vessels.[1-5] The reticuloendothelial system (RES), which comprises a network of macrophages and the endothelial lining of blood vessels, plays a vital role in the pathophysiology of SCD. This system is responsible for the clearance of abnormal cells, including sickled RBCs, as well as the regulation of immune responses and inflammation. In the context of SCD, the RES is tasked with removing damaged or dysfunctional RBCs from circulation, but its activities can also contribute to the inflammatory processes that exacerbate vaso-occlusive events. The interplay between the RES and sickled RBCs is critical for understanding the mechanisms driving VOCs in SCD.[6-10] Macrophages, as integral components of the RES, are primarily responsible for recognizing and phagocytosing sickled RBCs. This clearance process is essential for preventing the accumulation of damaged cells in the bloodstream, which could lead to further vascular obstruction. However, the phagocytosis of sickled cells by macrophages can trigger an inflammatory response characterized by the release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These

cytokines can amplify endothelial dysfunction, promoting the adhesion of sickled RBCs and leukocytes to the vascular endothelium, thereby increasing the risk of microvascular occlusion.[11-15]

Endothelial cells play a critical role in regulating vascular tone and maintaining blood flow. In SCD, the interactions between sickled RBCs, macrophages, and endothelial cells are significantly altered. The inflammatory cytokines released by activated macrophages can lead to the upregulation of adhesion molecules on endothelial cells, facilitating the adhesion of sickled RBCs and leukocytes to the vascular wall. This process creates a positive feedback loop that perpetuates the inflammatory response and increases the likelihood of vaso-occlusive crises.[16-18] The spleen, as a key organ within the RES, also plays a vital role in the clearance of abnormal RBCs. It acts as a filter for the blood, removing sickled and damaged RBCs from circulation. However, many individuals with SCD experience functional asplenia or hyposplenism due to repeated vaso-occlusive events and hemolysis. This loss of splenic function impairs the clearance of sickled RBCs and increases susceptibility to infections and other complications. The compromised ability of the spleen to filter sickled cells contributes to the heightened risk of vaso-occlusive crises in this population.[19-23] In addition to their role in cell clearance, macrophages within the RES are also involved in modulating hematopoiesis. The inflammatory environment created by the interaction of sickled RBCs and macrophages can influence the proliferation and differentiation of hematopoietic stem cells in the bone marrow. This disruption can lead to ineffective erythropoiesis, exacerbating anemia and increasing the risk of vaso-occlusive events. Understanding the effects of the RES on hematopoiesis is critical for addressing the overall health and management of individuals with SCD.[24-28] Given the significant role of the reticuloendothelial system in the pathogenesis of vaso-occlusive crises, targeting RES-mediated processes presents potential therapeutic avenues for managing SCD. Anti-inflammatory agents that can reduce cytokine release or block inflammatory signaling pathways may help mitigate the inflammatory response associated with vaso-occlusive crises. Additionally, strategies aimed at enhancing the clearance of sickled RBCs or improving splenic function could provide therapeutic benefits in reducing the incidence of vaso-occlusion.[29-32]

Mechanisms of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion

The reticuloendothelial system (RES) plays a crucial role in the clearance of sickled red blood cells (RBCs) from circulation. This process is primarily facilitated by macrophages, which are abundant in the spleen, liver, and bone marrow. Macrophages recognize and phagocytose sickled RBCs through various receptor-mediated mechanisms, including the recognition of exposed phosphatidylserine on the surface of damaged cells. Efficient clearance of sickled cells is essential to prevent their accumulation in the bloodstream, which can lead to further vascular obstruction and exacerbation of vaso-occlusive events. However, the rapid turnover of sickled RBCs can lead to increased hemolysis and release of free hemoglobin, contributing to further complications such as oxidative stress and endothelial dysfunction.[33-37] The interaction between sickled RBCs and the RES activates inflammatory pathways that significantly contribute to the pathogenesis of vaso-occlusive crises in sickle cell disease (SCD). Upon engulfing sickled RBCs, macrophages release pro-inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These cytokines play a critical role in recruiting additional immune cells to the site of inflammation, amplifying the inflammatory response. The chronic inflammation resulting from this process can lead to endothelial dysfunction, characterized by the impairment of

vascular relaxation and increased expression of adhesion molecules, which facilitates the adhesion of sickled RBCs and leukocytes to the vascular endothelium, ultimately promoting microvascular occlusion and VOCs.[38-42]

Endothelial cells are vital for maintaining vascular integrity and regulating blood flow. In the context of SCD, the inflammatory cytokines released by activated macrophages can lead to endothelial dysfunction. This dysfunction manifests as increased expression of adhesion molecules (such as selectins and integrins) and decreased production of vasodilatory factors like nitric oxide (NO). The loss of NO bioavailability due to oxidative stress and scavenging by free hemoglobin can result in impaired vasodilation and increased vascular resistance. Consequently, the combination of endothelial activation and the presence of sickled RBCs creates a microenvironment conducive to vaso-occlusion, further aggravating the clinical manifestations of SCD.[43-47] The spleen, as an essential organ within the RES, plays a critical role in filtering abnormal RBCs from circulation. It is responsible for removing sickled and damaged RBCs, thus preventing their accumulation in the bloodstream. However, individuals with SCD often experience functional asplenia or hyposplenism due to recurrent vaso-occlusive events, splenic sequestration, and hemolysis. The impairment of splenic function leads to reduced clearance of sickled RBCs, which can further exacerbate the risk of vaso-occlusive crises. Additionally, asplenia is associated with increased susceptibility to infections, particularly from encapsulated organisms, compounding the clinical challenges faced by individuals with SCD.[48-52] Macrophages within the RES are not only involved in the clearance of sickled RBCs but also play a role in modulating the immune response. The inflammatory environment created by sickled cells can influence the activation and polarization of macrophages, leading to either pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes. In SCD, the predominant pro-inflammatory response can perpetuate a cycle of inflammation that exacerbates endothelial dysfunction and increases the risk of vaso-occlusion. Moreover, the cross-talk between macrophages and other immune cells, such as T cells and neutrophils, further complicates the inflammatory milieu in SCD, highlighting the importance of understanding these interactions for potential therapeutic strategies.[53-56]

The RES also influences hematopoiesis, the process of blood cell formation, which occurs in the bone marrow. In SCD, the inflammatory cytokines released by macrophages can alter the bone marrow microenvironment, affecting the proliferation and differentiation of hematopoietic stem cells. Chronic inflammation can lead to ineffective erythropoiesis, exacerbating anemia and increasing the risk of vaso-occlusive events. Moreover, the interaction between sickled RBCs and the bone marrow microenvironment can influence the production of immature RBCs, which are more prone to sickling and contribute to further complications in SCD.[57-58] Oxidative stress is a prominent feature of SCD and is closely linked to the activities of the RES. The clearance of sickled RBCs by macrophages can result in the release of reactive oxygen species (ROS), which contribute to endothelial injury and dysfunction. Additionally, the release of free hemoglobin during hemolysis can scavenge nitric oxide (NO), leading to decreased NO availability and impaired vasodilation. The accumulation of oxidative stress within the vascular system can further exacerbate the inflammatory response, promoting a vicious cycle that heightens the risk of vaso-occlusive crises.[59] Given the significant role of the reticuloendothelial system in the pathogenesis of vaso-occlusive phenomena, targeting RES-mediated processes presents potential therapeutic avenues for managing SCD. Anti-inflammatory agents, antioxidants, and therapies aimed at enhancing macrophage function may help mitigate the inflammatory response associated with

vaso-occlusive crises. Additionally, strategies aimed at improving splenic function or compensating for asplenia could provide therapeutic benefits in reducing the incidence of vaso-occlusion and improving overall patient outcomes.[60] Healthcare providers should consider the role of inflammation, macrophage activity, and endothelial dysfunction when managing patients with SCD. Tailoring treatment approaches to address the underlying mechanisms associated with the RES may improve the management of vaso-occlusive crises and enhance the quality of life for individuals affected by sickle cell disease.[61-66]

Conclusion

The reticuloendothelial system (RES) plays a pivotal role in the pathophysiology of vaso-occlusive crises (VOC) in sickle cell disease (SCD). Through its multifaceted functions, including the clearance of sickled red blood cells (RBCs), modulation of inflammatory responses, and interaction with endothelial cells, the RES significantly influences the mechanisms underlying vaso-occlusion. The ability of macrophages within the RES to phagocytose sickled RBCs, coupled with their role in releasing pro-inflammatory cytokines, creates an environment that promotes endothelial dysfunction and exacerbates the risk of VOC. The compromised function of the spleen in individuals with SCD further complicates these processes, leading to impaired clearance of sickled cells and increased susceptibility to infections. Additionally, the interplay between oxidative stress and inflammation within the RES contributes to a vicious cycle that heightens the frequency and severity of vaso-occlusive events.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.

12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.

29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.

43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.

61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35
63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56
66. Obeagu EI. Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease. Elite Journal of Medical Sciences, 2024; 2(7):49-57